152 related articles for article (PubMed ID: 20065852)
1. The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma.
Koreishi AF; Saenz AJ; Persky DO; Cui H; Moskowitz A; Moskowitz CH; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):206-11. PubMed ID: 20065852
[TBL] [Abstract][Full Text] [Related]
2. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
Kelley TW; Pohlman B; Elson P; Hsi ED
Am J Clin Pathol; 2007 Dec; 128(6):958-65. PubMed ID: 18024321
[TBL] [Abstract][Full Text] [Related]
3. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.
Alvaro T; Lejeune M; Salvadó MT; Bosch R; García JF; Jaén J; Banham AH; Roncador G; Montalbán C; Piris MA
Clin Cancer Res; 2005 Feb; 11(4):1467-73. PubMed ID: 15746048
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.
Alvaro-Naranjo T; Lejeune M; Salvadó-Usach MT; Bosch-Príncep R; Reverter-Branchat G; Jaén-Martínez J; Pons-Ferré LE
Leuk Lymphoma; 2005 Nov; 46(11):1581-91. PubMed ID: 16236613
[TBL] [Abstract][Full Text] [Related]
5. Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.
Quesada AE; Assylbekova B; Jabcuga CE; Zhang R; Covinsky M; Rios A; Nguyen ND; Brown RE
Int J Clin Exp Pathol; 2015; 8(10):13241-8. PubMed ID: 26722524
[TBL] [Abstract][Full Text] [Related]
6. FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma.
Kiyasu J; Aoki R; Tanaka PY; Pracchia LF; Calore EE; Perez NM; Kimura Y; Niino D; Sugita Y; Takayanagi R; Abe Y; Matsuoka M; Ohshima K
Pathol Int; 2012 Feb; 62(2):77-83. PubMed ID: 22243776
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin.
Krenacs L; Wellmann A; Sorbara L; Himmelmann AW; Bagdi E; Jaffe ES; Raffeld M
Blood; 1997 Feb; 89(3):980-9. PubMed ID: 9028330
[TBL] [Abstract][Full Text] [Related]
8. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
Gupta GK; Agrawal T; Pilichowska M
BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
[TBL] [Abstract][Full Text] [Related]
10. Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
Bosch Príncep R; Lejeune M; Salvadó Usach MT; Jaén Martínez J; Pons Ferré LE; Alvaro Naranjo T
Ann Hematol; 2005 Oct; 84(10):661-6. PubMed ID: 15875183
[TBL] [Abstract][Full Text] [Related]
11. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
12. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
Muenst S; Hoeller S; Dirnhofer S; Tzankov A
Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
[TBL] [Abstract][Full Text] [Related]
13. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
Hasselblom S; Sigurdadottir M; Hansson U; Nilsson-Ehle H; Ridell B; Andersson PO
Br J Haematol; 2007 May; 137(4):364-73. PubMed ID: 17456059
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
15. Assessment and diagnostic utility of the cytotoxic T-lymphocyte phenotype using the specific markers granzyme-B and TIA-1 in esophageal mucosal biopsies.
Resnick MB; Finkelstein Y; Weissler A; Levy J; Yakirevich E
Hum Pathol; 1999 Apr; 30(4):397-402. PubMed ID: 10208460
[TBL] [Abstract][Full Text] [Related]
16. Elevated mRNA levels of CTLA-4, FoxP3, and granzyme B in BAL, but not in blood, during acute rejection of lung allografts.
Madsen CB; Nørgaard A; Iversen M; Ryder LP
Transpl Immunol; 2010 Oct; 24(1):26-32. PubMed ID: 20633650
[TBL] [Abstract][Full Text] [Related]
17. Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.
Nguyen TT; Frater JL; Klein J; Chen L; Bartlett NL; Foyil KV; Kreisel FH
Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):383-91. PubMed ID: 26067141
[TBL] [Abstract][Full Text] [Related]
18. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma.
Fu J; Zhang Z; Zhou L; Qi Z; Xing S; Lv J; Shi J; Fu B; Liu Z; Zhang JY; Jin L; Zhao Y; Lau GK; Zhao J; Wang FS
Hepatology; 2013 Jul; 58(1):139-49. PubMed ID: 22961630
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma.
Asano N; Suzuki R; Matsuo K; Kagami Y; Ishida F; Tamaru JI; Jin GS; Sato Y; Shimoyama Y; Yoshino T; Morishima Y; Nakamura S
Histopathology; 2007 May; 50(6):705-15. PubMed ID: 17493234
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
